Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.

Target Oncol · 2017 · PMC5700232 · PMID 29067644

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Combined treatment of dasatinib and ceritinib showed a trend towards higher cell viability inhibition when compared to the individual monotherapies (Fig. 7 a).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.